GLP1 Agonist Drug Market Size, Statistics, Growth Trend Analysis and Forecast Report, 2026 – 2036

The GLP-1 agonist market is segmented by drug type into long-acting agonists (once-weekly subcutaneous and oral formats) and short-acting agonists (daily or twice-daily agents). By molecule, the market spans semaglutide, tirzepatide, dulaglutide, liraglutide, exenatide, albiglutide, and orforglipron as an emerging small-molecule oral entrant. By route of administration, subcutaneous injectable pens represent the dominant format, with oral formulations gaining commercial traction. By indication, the market addresses type 2 diabetes, obesity and weight management, cardiovascular risk reduction, MASH/NAFLD, chronic kidney disease, and other emerging indications. By end-user setting, distribution flows through hospital pharmacies, retail pharmacies, and online pharmacies. By distribution channel, the market is further divided across specialty pharmacies, direct-to-patient models, compounding pharmacies, and telehealth platforms.